Loading company…
Polyneuron Pharmaceuticals, based in Basel, develops treatments for antibody-mediated autoimmune diseases.
Polyneuron Pharmaceuticals AG develops therapies for antibody-mediated autoimmune diseases using its proprietary Antibody-Catch platform, with candidates PN-1007 and PN-1018 aimed at anti-MAG neuropathy and Guillain-Barré Syndrome. Founded in 2014 and headquartered in Basel, Switzerland, the company has secured CHF 10.820 mn through five deals, most recently a CHF 1.200 mn grant from Innosuisse - Swiss Innovation Agency on April 14, 2021. It is recorded at the Series A stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in